These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy. Relph K; Annels N; Smith C; Kostalas M; Pandha H Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043 [TBL] [Abstract][Full Text] [Related]
6. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Skelding KA; Barry RD; Shafren DR Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760 [TBL] [Abstract][Full Text] [Related]
7. The Effects of Mesenchymal Stem Cells Loaded with Oncolytic Karbalaee R; Mehdizadeh S; Ghaleh HEG; Izadi M; Kondori BJ; Dorostkar R; Hosseini SM Curr Cancer Drug Targets; 2024; 24(9):967-974. PubMed ID: 38310465 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Annels NE; Arif M; Simpson GR; Denyer M; Moller-Levet C; Mansfield D; Butler R; Shafren D; Au G; Knowles M; Harrington K; Vile R; Melcher A; Pandha H Mol Ther Oncolytics; 2018 Jun; 9():1-12. PubMed ID: 29989024 [TBL] [Abstract][Full Text] [Related]
9. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Skelding KA; Barry RD; Shafren DR Breast Cancer Res Treat; 2009 Jan; 113(1):21-30. PubMed ID: 18256929 [TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. Annels NE; Mansfield D; Arif M; Ballesteros-Merino C; Simpson GR; Denyer M; Sandhu SS; Melcher AA; Harrington KJ; Davies B; Au G; Grose M; Bagwan I; Fox B; Vile R; Mostafid H; Shafren D; Pandha HS Clin Cancer Res; 2019 Oct; 25(19):5818-5831. PubMed ID: 31273010 [TBL] [Abstract][Full Text] [Related]
11. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Au GG; Lindberg AM; Barry RD; Shafren DR Int J Oncol; 2005 Jun; 26(6):1471-6. PubMed ID: 15870858 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells. Holmes M; Scott GB; Heaton S; Barr T; Askar B; Müller LME; Jennings VA; Ralph C; Burton C; Melcher A; Hillmen P; Parrish C; Errington-Mais F Mol Ther Oncolytics; 2023 Jun; 29():17-29. PubMed ID: 37077714 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis. Wang C; Lu N; Yan L; Li Y Virol J; 2023 Nov; 20(1):252. PubMed ID: 37919738 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA. Elsedawy NB; Nace RA; Russell SJ; Schulze AJ Mol Ther Oncolytics; 2020 Jun; 17():484-495. PubMed ID: 32529026 [TBL] [Abstract][Full Text] [Related]
15. Potent oncolytic activity of human enteroviruses against human prostate cancer. Berry LJ; Au GG; Barry RD; Shafren DR Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Au GG; Lincz LF; Enno A; Shafren DR Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493 [TBL] [Abstract][Full Text] [Related]
17. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Au GG; Beagley LG; Haley ES; Barry RD; Shafren DR Virol J; 2011 Jan; 8():22. PubMed ID: 21241513 [TBL] [Abstract][Full Text] [Related]
18. Quantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western. Gillespie PF; Rustandi RR; Swartz AR; Shang L; Raffaele J; Prout A; Cunningham N; Dawod M; Deng JZ; Wang S; Olson J; Shieh Y; Loughney JW Hum Gene Ther; 2023 Jan; 34(1-2):68-77. PubMed ID: 36503264 [TBL] [Abstract][Full Text] [Related]
19. [Oncolytic coxsackievirus therapy as an immunostimulator]. Miyamoto S; Sagara M; Kohara H; Tani K Rinsho Ketsueki; 2017; 58(8):977-982. PubMed ID: 28883283 [TBL] [Abstract][Full Text] [Related]
20. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21. Johansson ES; Xing L; Cheng RH; Shafren DR J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]